

1 **Seroprevalence of the hepatitis E virus among blood**

2 **donors in the Qassim Region, Saudi Arabia**

3 Bader Y. Alhatlani<sup>1\*</sup>, Waleed A. Aljabr<sup>2</sup>, Mohammed S. Almarzouqi<sup>1</sup>, Sami M. Alhatlani<sup>3</sup>,

4 Rayan N. Alzunaydi<sup>3</sup>, Abeer S. Alsaykhan<sup>3</sup>, Sulaiman H. Almaiman<sup>3</sup>, Ahmed A. Aleid<sup>4</sup>,

5 Ammar H. Alsughayir<sup>5</sup>, Yara E. Bishawri<sup>2</sup>, Abdulrahman A. Almusallam<sup>1</sup>

6

7 <sup>1</sup>Department of Medical Applied Sciences, Unayzah Community College, Qassim University,

8 Unayzah, Saudi Arabia

9 <sup>2</sup>Research Centre, King Fahad Medical City, Riyadh, Saudi Arabia

10 <sup>3</sup>Blood Donor Unit, Medical Laboratory Department, King Saud Hospital, Unayzah, Saudi

11 Arabia

12 <sup>4</sup>Gastroenterology and Hepatology Department, King Fahad Medical City, Riyadh, Saudi

13 Arabia

14 <sup>5</sup>Transfusion Medicine and Hematopathology Department, King Fahad Medical City, Riyadh,

15 Saudi Arabia

16

17 \*Corresponding author

18 E-mail: [balhatlani@qu.edu.sa](mailto:balhatlani@qu.edu.sa) (BYA)

19

20 **Short title:** Prevalence of hepatitis E in blood donors in the Qassim Region

21

22

23

24

25

## 26 **Abstract**

27 The aim of this study was to evaluate the seroprevalence of hepatitis E virus (HEV), a major  
28 public health issue worldwide with the potential for transmission via blood transfusion, in  
29 blood donors in the Qassim Region, Saudi Arabia. Serum samples (n = 1,078) were collected  
30 from volunteer blood donors from January to April 2019 and tested for the presence of anti-  
31 HEV IgG and IgM by indirect enzyme-linked immunosorbent assays. Overall, the  
32 seroprevalence of anti-HEV IgG and IgM among blood donors was 5.7% and 1.3%,  
33 respectively. Additionally, the seropositive rates of anti-HEV IgG and IgM were significantly  
34 higher in non-Saudi donors (22.1% and 7.8%) than in Saudi donors (3% and 0.2%). The  
35 seroprevalence of anti-HEV IgG increased with age; however, there was no correlation  
36 between gender and anti-HEV IgG and/or IgM. The seroprevalence of HEV among blood  
37 donors in the Qassim Region was lower than previous estimates for other regions of the  
38 country. Further studies covering a wider geographical area are needed to validate and  
39 expand the findings and to determine the importance of HEV screening in the region.

40

41

42

43

44

## 45 **Introduction**

46           Hepatitis E virus (HEV), belonging to the *Orthohepevirus* genus in the family  
47 *Hepeviridae*, causes liver diseases in humans [1]. The virus was first described in the early  
48 1980s as a non-A and non-B hepatitis virus and was subsequently cloned in 1991 [2,3]. HEV  
49 contains a small nonenveloped, positive-sense single-stranded RNA genome approximately  
50 7,200 nucleotides long [4]. HEV is an etiological agent of hepatitis E in humans. Similar to  
51 hepatitis A, the vast majority of HEV infections are asymptomatic (especially in children) or  
52 cause self-limiting acute liver inflammation, which can resolve within a few weeks without  
53 the need for specific treatment [4]. However, immunosuppressed individuals, organ-  
54 transplant recipients, hemodialysis patients, and pregnant women are at a high risk of  
55 developing life-threatening diseases, including chronic hepatitis and acute liver failure, after  
56 infection with HEV [5,6]. It has been estimated that the mortality rates for HEV infections in  
57 pregnant women and young people are about 20% and 3%, respectively [7]. The incubation  
58 period, which occurs during the prodromal phase, can vary from 2 to 8 weeks, and common  
59 symptoms of HEV infection during this period are usually nonspecific and include fever,  
60 nausea, vomiting, and malaise [8]. HEV is now recognized as a major public health issue,  
61 causing over 20 million infections every year worldwide and accounting for approximately  
62 70,000 deaths [1]. Currently, there are eight known HEV genotypes from only one serotype  
63 that can infect humans and other animal taxa (HEV-1 to HEV-8), of which HEV-1 and HEV-  
64 2 are restricted to humans and are associated with most outbreaks in developing countries in  
65 parts of Asia, Central America, and Africa [9]. Genotypes 3 and 4 are typically identified in  
66 developed countries, including the USA, New Zealand, Japan, and some countries in Europe,  
67 and can be isolated from a broader range of taxa, including humans, pigs, deer, and rabbits.  
68 Genotypes 5 and 6 are found in wild boars [8,10]. More recently, a new genotype of camelid

69 HEV (HEV-7) was isolated from dromedary camels in the UAE and some African countries,  
70 including Sudan and Egypt [11,12].

71 Fecal-oral transmission is considered the main route of HEV transmission, but other  
72 transmission routes have been suggested. This includes person-to-person transmission, such  
73 as vertical transmission (mother-to-infant) during delivery. In particular, blood transfusion  
74 transmission has become one of the main routes, especially in some low-income countries in  
75 Asia [4]. Several studies have reported transfusion-transmitted HEV from blood components  
76 in many industrialized countries, including European countries, Australia, and the United  
77 States [13-18]. In the Gulf and other neighboring countries, few studies have evaluated the  
78 HEV seroprevalence in healthy blood donors. A recent study has indicated that the HEV  
79 seroprevalence in Qatar is high among blood donors, i.e., approximately 21% [19]. To the  
80 best of our knowledge, the first study of HEV in Saudi Arabia was conducted in 1994 in  
81 Riyadh and Gizan, with anti-HEV antibody detection frequencies of 8.4% and 14.9%,  
82 respectively [20]. Two additional studies of HEV in Saudi Arabia reported seroprevalences in  
83 blood donation samples of 18.7% and 16.9% in Makkah and Jeddah, respectively [21,22]. In  
84 most countries, screening is not available for HEV in blood donors. However, in the  
85 Netherlands, screening was introduced in 2017, and the United States is now considering  
86 HEV screening for blood donors [4]. In this study, we estimated the HEV seroprevalence  
87 among blood donors in the Qassim Region, Saudi Arabia. These results provide a basis for  
88 evaluating whether routine screening is necessary in Saudi Arabia.

89

## 90 **Materials and methods**

### 91 **Ethics statement and sample collection**

92 From January to April 2019, 1,078 whole blood samples were collected from  
93 volunteer blood donors at the Blood Donor Unit at King Saud Hospital, Unayzah, Saudi  
94 Arabia. All study participants provided written informed consent, and the study design was  
95 approved by the local research Ethical Committee of the General Directorate of Health  
96 Affairs at Qassim Province (approval number: 1441-225162).

97

## 98 **Serological testing**

99 Serum samples were tested for the presence of anti-HEV IgG and IgM antibodies  
100 using commercial HEV Enzyme-linked Immunosorbent Assay (ELISA) Kits (Fortress  
101 Diagnostics, Antrim, UK) according to the manufacturer's instructions. The sensitivity and  
102 specificity of the assays are 99.5% and 99.6%, respectively [23]. Samples were tested in  
103 duplicate and samples yielding borderline results were retested in duplicate to confirm the  
104 initial results. Only IgG-positive samples were tested for the presence of anti-HEV IgM.

105

## 106 **Statistical analyses**

107 The Chi-square test and Fisher's exact test with the Freeman-Halton extension were  
108 used to evaluate the associations between the demographic characteristics of the participants  
109 and HEV seroprevalence. All statistical analyses were performed using an online statistical  
110 calculator at: (<https://www.socscistatistics.com>); a two-tailed  $p$ -value of 0.05 was considered  
111 significant.

112

## 113 **Results**

114 Whole blood samples ( $n = 1,078$ ) were collected from blood donors at King Saud  
115 Hospital in the Qassim Region, Saudi Arabia. General characteristics of the blood donors are

116 summarized in Table 1. The study population included 1,002 (93%) men and 76 (7%)  
117 women, with 924 (85.7%) Saudis and 154 (14.3%) non-Saudis with different nationalities.  
118 The age of participants ranged from 18 to 73 years (mean  $\pm$  SD, 34.5  $\pm$  10.3 years); 461  
119 donors (42.8%) were aged 25 to 34 years, 202 donors (18.7%) were younger than 25 years,  
120 and 61 donors (5.7%) were older than 55 years (Table 1).

121

122 **Table 1. Characteristics of the study population and anti-HEV IgG results.**

<u>Gender</u>	<u>Total (n = 1,078)</u>	<u>HEV IgG-positive</u>	<u>HEV IgG-negative (n</u>	<u>p-value</u>
	76 (7%)	(n = 61)	= 1,017)	
Female	1,002 (93%)	2 (2.6%)	74 (97.4%)	0.24
Male		59 (5.9%)	943 (94.1%)	
<u>Nationality</u>				
Saudi	924 (85.7%)	27 (3%)	897 (97%)	<0.001
Non-Saudi	154 (14.3%)	34 (22.1%)	120 (77.9%)	
<u>Age group (years)</u>				
<25	202 (18.7%)	2 (1%)	200 (99%)	
25–34	461 (42.8%)	28 (6%)	433(94%)	0.01
35–44	247 (22.9%)	16 (6.5%)	231 (93.5%)	
45–54	107 (9.9%)	11 (10.3%)	96 (89.7%)	
$\geq$ 55	61 (5.7%)	4 (6.5%)	57 (93.5%)	

123

124

125 In total, 61 of the 1,078 blood samples (5.7%) were positive for anti-HEV IgG,  
126 including 2 samples from women (2.6%) and 59 from men (5.9%), with no significant  
127 difference between males and females ( $p = 0.24$ ). However, the anti-HEV IgG seroprevalence  
128 was significantly higher in non-Saudis (22.1%) than in Saudis (3%) (Table 1,  $p < 0.001$ ). We  
129 also analyzed the same blood donor samples for the seroprevalence of anti-HEV IgM. Our  
130 results indicated that 14 of the 1,078 serum samples (1.3%) were positive for anti-HEV IgM  
131 (Table 2). Again, the seroprevalence of anti-HEV IgM was significantly higher in blood  
132 samples from non-Saudis (7.8%) than in those from Saudi donors (0.2%) (Table 2,  $p <$

133 0.001). No significant differences were found in the frequencies of anti-HEV IgM-positive  
134 samples between women and men ( $p = 0.99$ ).

135

136 **Table 2. Characteristics of the study population and anti-HEV IgM results.**

<u>Gender</u>	<u>Total</u> (n = 1,078)	<u>HEV IgM-positive</u> (n = 14)	<u>HEV IgM-negative (n =</u> <u>1,064)</u>	<u>p-value</u>
Female	76 (7%)	1 (1.3%)	75 (99%)	0.99
Male	1,002 (93%)	13 (1.3%)	989 (99%)	
<u>Nationality</u>				
Saudi	924 (85.7%)	2 (0.2%)	922 (99.8%)	<0.001
Non-Saudi	154 (14.3%)	12 (7.8%)	142 (92.2%)	
<u>Age group (years)</u>				
<25	202 (18.7%)	2 (1%)	200 (99%)	0.72
25–34	461 (42.8%)	6 (1.3%)	455 (98.7%)	
35–44	247 (22.9%)	5 (2%)	242 (98%)	
45–54	107 (9.9%)	1 (1%)	106 (99%)	
≥55	61 (5.7%)	0 (0%)	61 (0%)	

137

138 Furthermore, we found a significantly higher rate of HEV IgG-positive samples for  
139 donors between 45 to 54 years old (10.3%,  $p = 0.01$ ) than for other age groups, while donors  
140 younger than 25 years old had only an anti-HEV IgG seropositive rate of 1% (Fig 1). The  
141 other age groups had similar anti-HEV IgG seropositive rates, and there was no significant  
142 association between age groups and anti-HEV IgM seropositivity ( $p = 0.72$ ).

143

144 **Figure 1. Age distributions of 1,078 blood donors positive for anti-HEV IgG and/or**  
145 **IgM.**

146

147 Of the 14 anti-HEV IgM-positive serum samples, only two samples tested positive for  
148 anti-HCV antibodies, both of which were from male non-Saudi donors. There was no  
149 significant association between anti-HEV and anti-HCV. In addition, none of the samples  
150 were positive for anti-HBsAg, anti-HIV, and anti-HTLV I/II.

151

## 152 **Discussion**

153 HEV is a transfusion-transmissible virus, as evidenced by its detection in blood  
154 donors in both developed and developing countries [24,25]. In the current study, we screened  
155 1,078 serum samples from blood donors in the Qassim Region, Saudi Arabia for anti-HEV  
156 IgG and IgM antibodies. This is the largest study of the seroprevalence of HEV in Saudi  
157 Arabia to date with respect to the number of samples obtained from blood donors. Our results  
158 indicated that the seroprevalence of HEV in blood donors is 5.7% for IgG and 1.3% for IgM.  
159 In addition, we detected a significant difference between Saudis (3%) and non-Saudis  
160 (22.1%) in the seroprevalence of anti-HEV IgG. The seroprevalence of anti-HEV IgM was  
161 also significantly higher among non-Saudi blood donors (7.8%) than in Saudi blood donors  
162 (only 0.2%). Moreover, we found an increase in the rate of anti-HEV IgG with age. The  
163 highest rate of positive anti-HEV IgG results was observed in the 45- to 54-year-old group  
164 and the lowest rate was obtained for donors younger than 25 years (Fig 1). These results are  
165 consistent with those of a previous study suggesting that age is a risk factor for HEV [26].  
166 The anti-HEV IgM seroprevalence was comparable in all age groups other than donors aged  
167 over 55 years who tested negative for IgM. Some studies have suggested that the HEV  
168 seroprevalence rate increases with age, while other studies have reported that the correlation  
169 between age groups and HEV seroprevalence varies [13, 22]. The anti-HEV IgG  
170 seroprevalence among blood donors in the Qassim Region was comparable to that in Riyadh  
171 (8.4%) but was much lower than estimates for other regions of Saudi Arabia, such as Gizan  
172 (14.9%), Makkah (18.7%), and Jeddah (16.9%) [20-22]. Moreover, the seroprevalence of  
173 anti-HEV IgG was also lower than that reported in neighboring countries, such as Qatar  
174 (20.7%) [19]. This variation in the HEV seroprevalence among studies can be explained by  
175 differences in the commercial enzyme immunoassays used to detect HEV antibodies in blood  
176 donor samples. Commercial ELISA assays have different sensitivities and specificities,  
177 which may lead to variation in estimates of the HEV seroprevalence [23]. For instance, the



178 HEV ELISA kit used in the present study (Fortress Diagnostics) has a sensitivity and  
179 specificity of 99.5% and 99.6%, respectively, but the most common ELISA for HEV  
180 detection (the Wantai assay) is known for its high antibody detection rates [24]. In addition,  
181 these assays may not detect all HEV genotypes. The variation among studies may also be  
182 explained by differences in demographic properties, which can vary among cities within the  
183 same country. For example, the higher HEV seroprevalence in Makkah and Jeddah compared  
184 to other cities in Saudi Arabia could be due to the high number of visitors of different  
185 nationalities in these two cities every year for pilgrimages and other religious practices. A  
186 potential limitation of the current study is that we could not confirm the presence of HEV  
187 RNA in the seropositive donor samples.

188 In summary, we showed that the seroprevalence of HEV is relatively low (5.7% and  
189 1.3% for anti-HEV IgG and IgM, respectively) among blood donors in the Qassim Region,  
190 Saudi Arabia when compared to those in other regions of the country. The anti-HEV IgG  
191 seropositivity was significantly higher in non-Saudi donors (22.1%) than in Saudi donors  
192 (3%). Further investigations of the seroprevalence of HEV in a larger sample of blood donors  
193 from an expanded geographical distribution are needed to determine the need for HEV  
194 screening for blood donors in Saudi Arabia.

195

## 196 **Acknowledgments**

197 The authors gratefully thank all the staff in the Medical Laboratory Department at  
198 King Saud Hospital for their contribution to this study. We also would like to thank Editage  
199 ([www.editage.com](http://www.editage.com)) for English language editing.

200

## 201 **References**

- 202 1. Debing Y, Moradpour D, Neyts J, Gouttenoire J. Update on hepatitis e virology:  
203 Implications for clinical practice. *J Hepatol*. 2016;65(1): 200–212. doi:  
204 10.1016/j.jhep.2016.02.045.
- 205 2. Balayan MS, Andjaparidze AG, Savin Skaya SS, Ketiladze ES, Braginsky DM,  
206 Suvinov AP, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the  
207 fecal-oral route. *Intervirology*. 1983;20: 23–31. doi: 10.1159/000149370
- 208 3. Reyes GR, Purdy MA, Kim JP, Luk KC, Young LM, Fry KE, et al. Isolation of a  
209 cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis.  
210 *Science* 1990;247: 1335–1339. doi: 10.1126/science.2107574.
- 211 4. Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, et al. Hepatitis  
212 E virus infection. *Nat Rev Dis Primers*. 2017;3:17086. doi: 10.1038/nrdp.2017.86.
- 213 5. Kamar N, Selves J, Mansuy J-M, Ouezzani L, Péron J-M, Guitard J, et al. Hepatitis E  
214 virus and chronic hepatitis in organ-transplant recipients. *N Engl J Med*. 2008;358:  
215 811–817. doi: 10.1056/NEJMoa0706992.
- 216 6. Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. *Clin*  
217 *Microbiol Rev*. 2014;27: 116–138. doi: 10.1128/CMR.00057-13.
- 218 7. Mushahwar IK. Hepatitis E virus: Molecular virology, clinical features, diagnosis,  
219 transmission, epidemiology, and prevention. *J Med Virol*. 2008;80: 646–658. doi:  
220 10.1002/jmv.21116.
- 221 8. Pérez-Gracia MT, García M, Suay B, Mateos-Lindemann ML. Current knowledge on  
222 hepatitis E. *J Clin Transl Hepatol*. 2015;3: 117–126.
- 223 9. Sooryanarain H, Meng XJ. Hepatitis E virus: reasons for emergence in humans. *Curr*  
224 *Opin Virol*. 2019;34: 10–17. doi: 10.1016/j.coviro.2018.11.006.
- 225 10. Forni D, Cagliani R, Clerici M, Sironi M. Origin and dispersal of Hepatitis E virus.  
226 *Emerg Microbes Infect*. 2018;7(1): 11. doi: 10.1038/s41426-017-0009-6.

- 227 11. Woo PCY, Lau SKP, Teng JLL, Tsang AKL, Joseph M, Wong EYM, et al. New  
228 hepatitis E virus genotype in camels, the Middle East. *Emerg Infect Dis.* 2014;20:  
229 1044–1048. doi: 10.3201/eid2006.140140.
- 230 12. Sridhar S, Teng JLL, Chiu TH, Lau SKP, Woo PCY. Hepatitis E virus genotypes and  
231 evolution: Emergence of camel hepatitis E variants. *Int J Mol Sci.* 2017;18: E869.  
232 doi: 10.3390/ijms18040869.
- 233 13. Kaufmann A, Kenfak-Foguena A, André C, Canellini G, Bürgisser P, Moradpour D,  
234 et al. Hepatitis E virus seroprevalence among blood donors in Southwest Switzerland.  
235 *PLoS One.* 2011;6: e21150. doi: 10.1371/journal.pone.0021150
- 236 14. Vollmer T, Diekmann J, Johne R, Eberhardt M, Knabbe C, Dreier J. Novel approach  
237 for detection of hepatitis E virus infection in German blood donors. *J Clin Microbiol.*  
238 2012;50: 2708–2713. doi: 10.1128/JCM.01119-12.
- 239 15. Gallian P, Lhomme S, Piquet Y, Sauné K, Abravanel F, Assal A, et al. Hepatitis E  
240 virus infections in blood donors, France. *Emerg Infect Dis.* 2014;20: 1914–1917.  
241 <https://doi.org/10.3201/eid2011.140516>.
- 242 16. Pawlotsky JM. Hepatitis E screening for blood donations: an urgent need? *Lancet.*  
243 2014;384: 1729–1730. doi: 10.1016/S0140-6736(14)61187-9.
- 244 17. Shrestha AC, Shrestha AC, Seed CR, Flower RLP, Rooks KM, Keller AJ, et al.  
245 Hepatitis E virus and implications for blood supply safety, Australia. *Emerg Infect*  
246 *Dis.* 2014;20: 1940–1942. doi: 10.3201/eid2011.140412.
- 247 18. Ticehurst JR, Pisanic N, Forman MS, Ordak C, Heaney CD, Ong E, et al. Probable  
248 transmission of hepatitis E virus (HEV) via transfusion in the United States.  
249 *Transfusion.* 2019;59: 1024–1034. doi: 10.1111/trf.15140.
- 250 19. Nasrallah GK, Al Absi ES, Ghandour R, Ali NH, Taleb S, Hedaya L, et al.  
251 Seroprevalence of hepatitis E virus among blood donors in Qatar (2013-2016).

- 252 Transfusion. 2017;57: 1801–1807. doi: 10.1111/trf.14116.
- 253 20. Arif M, Qattan I, al-Faleh F, Ramia S. Epidemiology of hepatitis E virus (HEV)  
254 infection in Saudi Arabia. *Ann Trop Med Parasitol*. 1994;88: 163–168. doi:  
255 10.1080/00034983.1994.11812854.
- 256 21. Abdelaal M, Zawawi TH, al Sobhi E, Jeje O, Gilpin C, Kinsara A, et al.  
257 Epidemiology of hepatitis E virus in male blood donors in Jeddah, Saudi Arabia. *Ir J*  
258 *Med Sci*. 1998;167: 94–96. doi: 10.1007/bf02937946.
- 259 22. Johargy AK, Mahomed MF, Khan MM, Kabrah S. Anti-hepatitis E virus  
260 seropositivity in a group of male blood donors in Makkah, Saudi Arabia. *J Pak Med*  
261 *Assoc*. 2013;63: 185–189.
- 262 23. Al-Sadeq DW, Majdalawieh AF, Mesleh AG, Abdalla OM, Nasrallah GK. Laboratory  
263 challenges in the diagnosis of hepatitis E virus. *J Med Microbiol*. 2018;67: 466–480.  
264 doi: 10.1099/jmm.0.000706.
- 265 24. Nelson KE. Transfusion transmission of hepatitis E virus: an emerging issue. *Ann*  
266 *Blood*. 2017;2: 1-7. doi: 10.21037/aob.2017.09.02.
- 267 25. Capai L, Charrel R, Falchi A. Hepatitis E in high-income countries: What do we  
268 know? And what are the knowledge gaps? *Viruses*. 2018;10: 1–23. doi:  
269 10.3390/v10060285.
- 270 26. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in  
271 developed countries. *Lancet Infect Dis*. 2008;8: 698–709. doi: 10.1016/S1473-  
272 3099(08)70255-X.

Samples positive for anti-HEV IgG and IgM, %

